FW: message to be approved

[Guest guest]

Painkillers and the Liver

Painkillers and the Liver

One of the most common questions that I am asked

by my

patients with hepatitis or other liver diseases

is - " Which

type of painkiller is safer for my liver -

acetaminophen

(Tylenol), or nonsteroidal anti-inflammatories

(such as

Aspirin, or Motrin)? " - Well, in this brief article

which is

excerpted from my book : " Dr. Palmer's

Guide To

Hepatitis and Liver Disease " I will answer this

question.

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=1

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-L2aOPiVCp75uHlR4@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

Hemispherx Affiliate Files Hepatitis C

Related Notice of Invention With the U.S. Patent

Office

Hemispherx Affiliate Files Hepatitis C Related

Notice of

Invention With the U.S. Patent Office

January 3, 2001

PHILADELPHIA--(BUSINESS WIRE)--Jan. 2, 2001 via

NewsEdge

Corporation -

Hemispherx Biopharma, Inc. (AMEX:HEB)(AMEX:HEBws)

announced

that the California Institute of Molecular

Medicine

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=2

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-OrRuPZeTX54iLbcW@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

Hemispherx Affiliate Files Hepatitis C

Related Notice of Invention With the U.S. Patent

Office

Hemispherx Affiliate Files Hepatitis C Related

Notice of

Invention With the U.S. Patent Office

January 3, 2001

PHILADELPHIA--(BUSINESS WIRE)--Jan. 2, 2001 via

NewsEdge

Corporation -

Hemispherx Biopharma, Inc. (AMEX:HEB)(AMEX:HEBws)

announced

that the California Institute of Molecular

Medicine

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=2

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-OrRuPZeTX54iLbcW@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

Axcan purchases patents on new, better

absorbed Ursodiol formulations from

Alfa-Wassermann and announces its investigative

intentions for new Ursodiol compounds

(note: this is the medicine, URSO, that I've been

on since

July,2000, and now have normal liver

enzymes!...........Sheree)

Axcan purchases patents on new, better absorbed

Ursodiol

formulations from Alfa-Wassermann and announces

its

investigative intentions for new Ursodiol

compounds

January 8, 2001

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=10

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-WtgQCO_ozcwMdzrF@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

SciClone Initiates U.S. Phase 2 Liver

Cancer Trial With ZADAXIN® Plus Radio Frequency

Ablation

SciClone Initiates U.S. Phase 2 Liver Cancer Trial

With

ZADAXIN® Plus Radio Frequency Ablation

January 9, 2001

SAN MATEO, Calif., Jan. 8 /PRNewswire/ via

NewsEdge

Corporation - SciClone Pharmaceuticals (Nasdaq:

SCLN) today

announced the initiation of a U.S. Phase 2 study

in patients

with hepatocellular carcinoma, evaluating the

effectiveness

of ZADAXIN®, the Company's immune system

enhancer, in

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=12

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-fUIPPMlWDFxv8XwU@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

SciClone Initiates U.S. Phase 2 Liver

Cancer Trial With ZADAXIN® Plus Radio Frequency

Ablation

SciClone Initiates U.S. Phase 2 Liver Cancer Trial

With

ZADAXIN® Plus Radio Frequency Ablation

January 9, 2001

SAN MATEO, Calif., Jan. 8 /PRNewswire/ via

NewsEdge

Corporation - SciClone Pharmaceuticals (Nasdaq:

SCLN) today

announced the initiation of a U.S. Phase 2 study

in patients

with hepatocellular carcinoma, evaluating the

effectiveness

of ZADAXIN®, the Company's immune system

enhancer, in

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=12

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-fUIPPMlWDFxv8XwU@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

SciClone Initiates U.S. Phase 2 Liver

Cancer Trial With ZADAXIN® Plus Radio Frequency

Ablation

SciClone Initiates U.S. Phase 2 Liver Cancer Trial

With

ZADAXIN® Plus Radio Frequency Ablation

January 9, 2001

SAN MATEO, Calif., Jan. 8 /PRNewswire/ via

NewsEdge

Corporation - SciClone Pharmaceuticals (Nasdaq:

SCLN) today

announced the initiation of a U.S. Phase 2 study

in patients

with hepatocellular carcinoma, evaluating the

effectiveness

of ZADAXIN®, the Company's immune system

enhancer, in

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=12

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-fUIPPMlWDFxv8XwU@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support

[Guest guest]

SciClone Initiates U.S. Phase 2 Liver

Cancer Trial With ZADAXIN® Plus Radio Frequency

Ablation

SciClone Initiates U.S. Phase 2 Liver Cancer Trial

With

ZADAXIN® Plus Radio Frequency Ablation

January 9, 2001

SAN MATEO, Calif., Jan. 8 /PRNewswire/ via

NewsEdge

Corporation - SciClone Pharmaceuticals (Nasdaq:

SCLN) today

announced the initiation of a U.S. Phase 2 study

in patients

with hepatocellular carcinoma, evaluating the

effectiveness

of ZADAXIN®, the Company's immune system

enhancer, in

--------------------

A complete copy of this message has been attached

for your convenience.

This message requires your approval for one of the

following reasons:

* Your group moderates all messages from this

user, OR

* Your group moderates messages from all users

To approve or reject this messages using the web,

please visit

pending/Hepatitis C

?view=12

To approve this message using email, reply to this

message. You do not

need to attach the original message, just reply

and send.

To reject this message using email, forward this

message to

Hepatitis C-reject-fUIPPMlWDFxv8XwU@egroup

s.com

Thank you for choosing eGroups as your email group

service for the Hepatitis C group.

Regards,

eGroups Customer Support